Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temodal vs Semustine in Recurrent Glioblastoma or Anaplastic Astrocytoma
NCT00335075Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2005
- Primary completion
- Feb 2006
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of temozolomide in glioblastoma (GBM), anaplastic astrocytoma (AA), sponsored by Merck & Co.. Started Mar 2005; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on NCT00335075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00335075.